ECONOMICAL ANALYSIS OF TENOFOVIR ALAFENAMIDE VERSUS TENOFOVIR DISOPROXIL

M Camean-Castillo, E. Rios-Sanchez, MD Gil-Sierra, MDP Briceño-Casado, FJ Salmeron-Navas, S. Fenix-Caballero, J Diaz-Navarro, C. Martinez-Diaz, EJ Alegre-DelRey, JM Borrero-Rubio

Hospital Universitario Puerto Real, Cádiz.

PURPOSE

The objective of the study is to assess the cost of using TAF instead of tenofovir-disoproxil fumarate (TDF) in a public health hospital.

MATERIAL AND METHODS

January 1st 2018 to October 31th 2018

Patients who used TDF in their HIV treatment regimens

Data of the different treatment regimens for HIV containing TDF and adherence to treatment were collected

The TDF treatments regimens were replaced by their commercial equivalent with TAF and the hospital acquisition prices were compared

The cost for each patient was calculated according to TDF or TAF presentation and extrapolated to one year of treatment

RESULTS

204 Patients

Adherence 95%

151 patients → TDF + emtricitabine + elvitegravir
16 patients → TDF + emtricitabine + darunavir/cobicistat
37 patients → TDF + emtricitabine + 3º drug

The patient cost and its annual potential cost are summarized in the following table

<table>
<thead>
<tr>
<th>Treatment Regimen</th>
<th>No. of Patients</th>
<th>Patient Cost</th>
<th>Annual Cost</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>TDF+emtricitabine+elvitegravir</td>
<td>151</td>
<td>560,22€</td>
<td>1.015.118,64€</td>
<td>300.393,36€</td>
</tr>
<tr>
<td>TAF+emtricitabine+elvitegravir</td>
<td>151</td>
<td>726€</td>
<td>1.315.512€</td>
<td>300.393,36€</td>
</tr>
<tr>
<td>TDF+emtricitabine+darunavir/cobicistat</td>
<td>16</td>
<td>380,65€</td>
<td>73.084,8€</td>
<td>103.171,2€</td>
</tr>
<tr>
<td>TAF+emtricitabine+darunavir/cobicistat</td>
<td>16</td>
<td>918€</td>
<td>176.256€</td>
<td>103.171,2€</td>
</tr>
<tr>
<td>TDF+emtricitabine+3º drug (not studied)</td>
<td>37</td>
<td>71,2€</td>
<td>13.852,8€</td>
<td>125.696,4€</td>
</tr>
<tr>
<td>TAF+emtricitabine+3º drug (not studied)</td>
<td>37</td>
<td>314,3€</td>
<td>139.549,2€</td>
<td>125.696,4€</td>
</tr>
</tbody>
</table>

CONCLUSION

Almost 75% of patients with TDF used a treatment regimen with emtricitabine + elvitegravir.
Adherence to treatment was excellent.
The consideration to switch TDF to TAF must take into account its associated cost due to the high impact that would imply.

J05 - Antivirals for systemic use 2SPD-005